Expert Insights on Key Updates From the 2022 ESMO Congress on PARP Inhibitors in Ovarian Cancer

Decera Clinical Education Oncology Podcast · Oct 4, 2022 · 19m

In this episode, Domenica Lorusso, MD, PhD, and Alexandra Leary, MD, PhD, provide their expert insights on key updates presented for ovarian cancer trials including:

Phase III GOG-3004/SOLO-1: OS results after 7 years of follow-up for patients with newly diagnosed advanced ovarian cancer receiving maintenance olaparib vs placebo

Phase III ENGOT-ov25/PAOLA-1: final OS results from the trial of maintenance therapy with olaparib with bevacizumab vs bevacizumab alone in women with newly diagnosed advanced ovarian cancer

Phase III ATHENA-MONO: outcomes by disease subgroups receiving rucaparib vs…